— Know what they know.
Not Investment Advice
WXXWY (OTC) is a cross-listing of 2269.HK (HKSE). Showing primary listing data.

2269.HK

WuXi Biologics (Cayman) Inc.
1W: -6.9% 1M: -18.8% 3M: -0.5% YTD: -17.4% 1Y: +55.2% 3Y: -54.5% 5Y: -65.0%
HK$31.54 ($4.03)
-1.60 (-4.83%)
 
HKSE · Healthcare · Biotechnology · HK$136.8B
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market CapHK$136.8B ($17.5B)
52W Range16.2-44
Volume48,165,399
Avg Volume33,744,297
Beta1.69
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOZhisheng Chen
Employees12,575
SectorHealthcare
IndustryBiotechnology
IPO Date2017-06-13
No. 108, Meiliang Road
Wuxi 214092
CN
86 51081831205
About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms